Labcorp extends ColoSense rollout, shares trade steadily on Xetra

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-28, 14:07.

Labcorp (US50540R4092) highlights the nationwide rollout of its ColoSense at-home colorectal cancer screening test this week. The diagnostics group is listed in New York on the NYSE under the ticker LH and also trades in Germany on Xetra, giving the stock a transatlantic investor base.

ColoSense launch in focus

On June 22, Labcorp announced that ColoSense, described as the first FDA-approved RNA-based at-home colorectal cancer screening test, is now available across the United States, with coverage for eligible Medicare and Medicare Advantage patients. The company positions the test as a differentiated option in colorectal screening that aligns with major U.S. guidelines on cancer prevention.

According to Labcorp's release, ColoSense uses RNA biomarker detection to target both colorectal cancer and advanced adenomas, combined with an at-home stool collection kit designed to simplify use for patients. MarketScreener notes the June 22 communication and lists Labcorp in the Healthcare Facilities & Services sector, with the shares recently quoted at 236.00 euros in Xetra trading.

How investors read the move

Analyst commentary picked up on the ColoSense news as a sign of Labcorp's attempt to reignite growth in its mature diagnostics business through new offerings. A recent article on Yahoo Finance describes the stock as having advanced about 6.1 percent following the FDA approval and Medicare coverage details, underlining investor interest in guideline-aligned at-home testing.

The same analysis stresses that while ColoSense adds a new lever for screening revenue, near-term drivers for the Labcorp equity still include the company's broader specialty testing pipeline, AI-related initiatives and execution on earnings momentum in a cost-conscious healthcare environment. For sector comparison, MarketScreener classifies Labcorp alongside other diversified diagnostics and laboratory services groups rather than pure equipment manufacturers.

The product behind the stock

Beyond ColoSense, Labcorp generates revenue predominantly from clinical laboratory testing services, central laboratory support for clinical trials and specialty diagnostics work for hospitals, physicians and biotech companies. The ColoSense test, as part of the colorectal screening suite, adds an RNA-based at-home option that complements Labcorp's existing colon cancer diagnostics portfolio.

Where the shares trade today

Labcorp shares (US50540R4092) most actively trade on the NYSE under the ticker LH, with additional quotation on Xetra identified by the code N6B and recent indicative pricing around 236.00 euros in the German venue as of 2026-06-26, 11:35.

Disclaimer: This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell Labcorp shares or any other securities.